Lamivudine Teva Pharma

Lamivudine, the active ingredient in Lamivudine Teva, is a nucleoside reverse transcriptase inhibitor presented as an oral dosage form for oral use. It treats HIV-1 infection and chronic hepatitis B in adults, helping to suppress viral replication and improve immune function.

GNH USA supplies Lamivudine Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lamivudine is used in antiretroviral therapy and hepatitis B management, targeting viral replication pathways. - HIV-1 infection: reduces plasma viral load and helps restore CD4+ T‑cell counts. - Chronic hepatitis B infection: suppresses HBV DNA synthesis and lowers liver inflammation. - Prevention of mother‑to‑child transmission of HIV: decreases the risk of vertical transmission during pregnancy and delivery.

Lamivudine is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Headache: transient cranial discomfort. - Fatigue: reduced energy levels. - Diarrhea: loose stools. - Insomnia: difficulty sleeping. - Abdominal pain: mild cramping.

Serious or Rare Side Effects: - Lactic acidosis: severe metabolic disturbance. - Hepatic steatosis: fatty liver disease. - Pancreatitis: inflammation of the pancreas. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Neutropenia: low white‑blood‑cell count. - Anemia: reduced red‑blood‑cell levels.

Before prescribing lamivudine, clinicians should consider several safety factors. - Renal impairment: assess kidney function and adjust dose if needed. - Hepatic impairment: monitor liver enzymes regularly. - Pregnancy: category B; use when benefits outweigh potential risks. - Lactation: minimal drug excretion in breast milk; monitor infant. - Resistance development: perform viral load testing to detect resistance. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Lamivudine may interact with other medicines, requiring vigilance.

Major Interactions (Avoid): - Didanosine: increased risk of pancreatitis. - Stavudine: heightened peripheral neuropathy risk. - Ribavirin: additive toxicity, especially hematologic.

Moderate Interactions (Monitor Closely): - Efavirenz: possible reduction in lamivudine plasma levels. - Tenofovir: combined renal toxicity potential. - Alcohol: may exacerbate liver injury.